+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the effects of negative pressure wound therapy NPWT compared to standard open wound care after surgical removal of chronic pilonidal sinus disease PSD. PSD is a persistent inflammatory skin condition often causing infection, abscesses, and pain, mainly affecting young adults. This study aims to improve post-operative and patient-reported outcomes following surgery for PSD. Participants undergo elective excision of their pilonidal sinus without primary closure. In one group, NPWT is applied using a foam-based system with continuous negative pressure and dressing changes every 48 to 72 hours until the wound heals. The other group receives standard wound care with open wound management and dressings as per local practice. Throughout the study, participants will be monitored for up to six months to assess wound healing time, pain levels, complications, recurrence rates, quality of life, scar appearance, and costs related to treatment. Data will be collected at various intervals including baseline, surgery day, and follow-up visits at 28 days, 3 months, and 6 months, with questionnaires and clinical assessments to evaluate outcomes.

Age: 18Years +All GendersPhase Not Applicable
10 locations
P

Actively Recruiting

Researchers are investigating whether using a genetic test called Prosigna4 can help decide if chemotherapy is necessary for premenopausal women with hormone receptor-positive HR and HER2-negative breast cancer. This study aims to determine if treatment guided by this test produces similar outcomes to the standard approach of systematic chemotherapy. The trial focuses on younger women who often experience more side effects from chemotherapy, affecting their quality of life and work capacity. Participants will be randomly assigned to one of two groups. In the experimental group, treatment depends on the Prosigna4 score women with a high score above 60 will receive chemotherapy plus hormone therapy, while those with a lower score will receive only hormone therapy with ovarian suppression. The control group will receive the standard treatment of chemotherapy followed by hormone therapy. The study includes a pre-inclusion period for eligibility testing and randomization. Throughout the study, participants will complete questionnaires about quality of life, treatment side effects, emotional well-being, and other health measures for up to five years after randomization. Researchers will monitor cancer recurrence, survival, fertility, osteoporosis, cardiovascular disease, and other outcomes. Regular assessments include physical activity levels, adherence to therapy, and patient perceptions of treatment and participation, aiming to evaluate the safety and impact of treatment guided by the genetic test.

Age: 35Years - 45YearsFEMALEPhase 3
105 locations